Dr. Nedal Safwat has been named chief strategy officer of Accelerate Diagnostics.
Dr. Nedal Safwat joins Accelerate from BioMerieux, the world’s leading microbiology diagnostics company.
Jack Phillips, President and Chief Executive Officer of Accelerate Diagnostics, commented, “We are excited to add a leader to our team with such extensive commercial and operational experience in the microbiology diagnostics space. In this newly created position as Chief Strategy Officer, Nedal will take a leadership role in the implementation of our recently launched new product strategy and will be responsible for driving the expansion of this strategy over the long term. I am confident that his experience in the microbiology industry and commitment to growth make him a great fit for our team as we continue to execute against our long-term vision for Accelerate Diagnostics.”
“I am thrilled to join Accelerate Diagnostics, as the company plays a critical role in delivering high medical value tests that are transforming the standard of care. In my new role, I look forward to working with the Accelerate team to continue delivering products that drive better clinical outcomes for patients, reinforce antibiotic stewardship, and lower the overall cost of the treatment of serious infections,” said Dr. Safwat.
Dr. Nedal Safwat brings significant experience in the microbiology diagnostics and life sciences industries. During his 11 years at BioMerieux, he held a variety of roles of increasing importance, including positions in sales, product management, global marketing, and, most recently, leading the ID/AST Franchise. Prior to joining BioMerieux, Dr. Safwat held positions at Luminex Corporation, Strategic Diagnostics Incorporated, Miltenyi Biotec Incorporated, and Bayer Diagnostics.
Dr. Safwat received his bachelor’s and doctorate degrees in biochemistry from North Carolina State University. He is also an alumni of CEDEP (The European Centre for Executive Development).